Knight Therapeutics Acquired by Eton Pharmaceuticals | Healthcare M&A Deal

Eton Pharmaceuticals has acquired Knight Therapeutics, a pharmacy business in Illinois, for an undisclosed amount. Eton Pharmaceuticals acquisitions focus on rare disease commercialization, and Knight Therapeutics provided U.S. supply and distribution rights for IMPAVIDO (miltefosine), an FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis. The agreement supports Eton’s orphan drug portfolio by enabling U.S. access to a treatment used in adults and adolescents over age 12 and weighing more than 30 kg, with Deer Park, Illinois as the buyer’s base. This add on acquisition is a strategic acquisition within healthcare M&A, expanding Eton Pharmaceuticals acquisitions through a supply and distribution arrangement with rights effective September 26, 2026.